The International Association for Cannabinoid Medicines (IACM) was founded in March 2000. The aim of the association is to advance knowledge on cannabis, cannabinoids, the endocannabinoid system, and related topics especially with regard to their therapeutic potential. The mission is achieved in particular through the following actions:
- Support for research into cannabis products and the endocannabinoid system;
- Promotion of exchange of information between researchers, health care practitioners, patients and the public;
- Preparation and dissemination of reliable information on the pharmacology, toxicology and therapeutic potential of cannabis and modulators of the endocannabinoid system;
- Monitoring and documentation of national and international developments with respect to cannabinoid therapeutics;
- Co-operation with other organisations and associations sharing the mission and goals of the IACM
The IACM declares that it is the right of doctors to be able to discuss the medicinal use of cannabis with their patients.
There are regular and associate members. Regular members elect the board of directors consisting of up to ten members and decide on the guidelines of the association. Associate members elect up to two patient representatives The patient representatives may participate with equal rights in the meetings of the Board of Directors. The complete statutory articles of the IACM can be downloaded here as a pdf file.
Members receive the newsletter of IACM (IACM-News). The IACM Bulletin is published in several languages on the internet. Free subscription with the online-form.